Form 4: Tango Therapeutics Director Equity Grant Disclosure

Director Sung Lee received a grant of 12,300 restricted stock units and 5,200 stock options as part of director compensation.

Summary

• Director Sung Lee was granted 12,300 restricted stock units (RSUs) on April 29, 2026.
• Director Sung Lee was granted 5,200 stock options with an exercise price of $22.06 on April 29, 2026.
• The grants were issued in accordance with the company's Non-Employee Director Compensation Policy.
• Following these transactions, the director holds 22,300 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director compensation.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• Issuance of equity results in minor dilution to existing shareholders.

Risks

• Vesting of equity is contingent upon the director's continuous service to the company.

Future Outlook

The equity grants are subject to multi-year vesting schedules, incentivizing long-term service and retention of the director.

Industry Context

StockSavvy.ai notes that standard equity compensation for board members is a routine practice in the biotechnology sector to ensure alignment between governance and long-term shareholder value.

Comparison to Industry Standards

• The grant structure follows standard industry practices for non-employee director compensation in mid-cap biotech firms.
• Vesting periods of three years are consistent with typical corporate governance benchmarks for equity awards.

Corporate Governance

Stakeholder Impact

• Minor dilution for existing shareholders due to new equity issuance.

Next Steps

• Vesting of RSU installments beginning January 2, 2027.
• Vesting of stock options over 36 months.

Key Dates

Keywords

Tango Therapeutics, TNGX, Form 4, Director Compensation, Equity Grant, Insider Ownership